Aquestive therapeutics, inc. AQST.US Overview
AQST AI Analysis & Strategy
Analysis Conclusion
The stock, with its moderate value rating, suggests that existing positions can be retained. For initiating new positions, it's advisable to wait for a value score above 4 and a dividend score of 2 or higher.
AQST Current Performance
1.36%
Aquestive therapeutics, inc.
0.98%
Avg of Sector
0.83%
S&P500
AQST Key Information
AQST Financial Forecast
Unit : USD
AQST Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | -0.24 | -100% | 41.2% | 8.72M | -34% | -28.7% | -143.7% |
| 2024Q2 | -0.13 | -333.3% | 8.3% | 13.54M | 4.2% | 3.2% | -13.7% |
| 2024Q1 | -0.03 | 70% | -72.7% | 20.1M | 51.8% | 62.4% | -106.4% |
| 2023Q4 | -0.17 | -254.5% | 88.9% | 12.05M | 8.3% | -1.7% | -61.4% |
| 2023Q3 | -0.12 | 47.8% | 50% | 13.21M | 23.6% | 13.6% | -15.7% |
AQST Profile
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.